Business Model ResilienceSHC has a durable business model with exposure to commercial pharmaceutical and medical devices, which are less volatile in an economic downturn due to the necessary nature of the products.
Regulatory ImpactNelson volumes are benefiting from new regulatory requirements across various end-markets, including bioprocessing and medtech.
Strategic ExpansionNelson is opening a new sterility assurance clean room, marking a significant milestone that should enhance the product portfolio and improve capabilities for pharma customers.